The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis

被引:7
作者
Ghazvini, Kiarash [1 ]
Kamali, Hossein [2 ]
Hosseininasab-nodoushan, Seyed-Abolfazl [3 ]
Keikha, Masoud [1 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Dept Microbiol & Virol, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran
[3] Kerman Univ Med Sci, Fac Med, Dept Microbiol & Virol, Kerman, Iran
关键词
Helicobacter pylori; CYP2C19; polymorphism; Proton-pump inhibitor; Eradication rate; Triple therapy; Lansoprazole; Esomeprazole; 1-WEEK TRIPLE THERAPY; HELICOBACTER-PYLORI; ERADICATION RATE; 1ST-LINE ERADICATION; GENETIC-POLYMORPHISM; CYTOCHROME P2C19; ACID INHIBITION; RABEPRAZOLE; INFECTION; ESOMEPRAZOLE;
D O I
10.1016/j.genrep.2021.101340
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: CYP2C19 genotypes induce H. pylori eradication rate in the patients receiving PPI-based treatment regimens. The present study aimed to evaluate the effect of CYP2C19 variants on the H. pylori eradication rate in naive patients treated with PPI-based anti -H. pylori therapies. Methods: A computer-assisted comprehensive literature search was done in the Scopus, Pubmed, Embase, and the Cochran Register of Controlled Trials (CENTRAL) databases, for the relevant studies to be collected with no limitation in the language and publication date. All statistic analyses were performed using Comprehensive meta analysis software. Eradication rate of H. pylori in different CYP2C19 genotypes was measured via event rate; In addition, we pooled the data by the odds ratio with 95% CI to evaluate the effect of CYP2C19 polymorphisms on the changes in the rates of H. pylori eradication as well as sup-grouping analysis for individual PPIs. Publication bias also was assessed via Begg's p-value, Egger's p-value, and funnel the plot. Results: The number of studies included in the present one was 38 studies with 7079 data from the patients. H. pylori eradication rates in HomEMs, HetEMs and PMs were 77%, 82.7% and 85.4%, respectively. We observed a significant difference in H. pylori eradication rates between the HomEMs vs. HetEMs (OR: 0.69; 95% CI: 0.57-0.85), HomEMs vs. PMs (OR: 0.57; 95% CI: 0.46-0.72), as well as HetEMs vs. PMs (OR: 0.70; 95% CI: 0.56-0.87). However, the subgroup analysis was performed due to significant heterogeneity. A significantly lower eradication rate in HomEMs vs. HetEMs (OR: 0.34; 95% CI: 0.22-0.52) and HomEMs vs. PMs (OR: 0.22; 95% CI: 0.10-0.47) for Omeprazole as well as HomEMs vs. HetEMs (OR: 0.56; 95% CI: 0.39-0.82) for Lansoprazole or HomEMs vs. PMs (0.57; 95% CI: 0.33-1.00) were observed for Esomeprazole. Conclusion: The H. pylori eradication rate in HomEM, HetEM, and PM was 77%, 82.7%, and 85.4% respectively. Moreover, the clinical efficacy of Omeprazole, Lansoprazole, and Esomeprazole-based first-line therapies is significantly dependent on the CYP2C19 genotype status, while polymorphisms of this gene have no significant effect on the efficacy of Pantoprazole and Rabeprazole-based diets.
引用
收藏
页数:9
相关论文
共 98 条
[41]   Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy [J].
Kuo, Chao-Hung ;
Wang, Sophie S. W. ;
Hsu, Wen-Hung ;
Kuo, Fu-Chen ;
Weng, Bi-Chuang ;
Li, Chia-Jung ;
Hsu, Ping-I ;
Chen, Angela ;
Hung, Wen-Chun ;
Yang, Yuan-Chieh ;
Wang, Wen-Ming ;
Wu, Deng-Chyang .
HELICOBACTER, 2010, 15 (04) :265-272
[42]   Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial [J].
Kuo, Chao-Hung ;
Hu, Hung-Ming ;
Kuo, Fu-Chen ;
Hsu, Ping-I. ;
Chen, Angela ;
Yu, Fang-Jung ;
Tsai, Pei-Yun ;
Wu, I. -Chen ;
Wang, Sheng-Wen ;
Li, Chia-Jung ;
Weng, Bi-Chuang ;
Chang, Lin-Li ;
Jan, Chang-Ming ;
Wang, Wen-Ming ;
Wu, Deng-Chyang .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (05) :1017-1024
[43]   Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients [J].
Kurzawski, Mateusz ;
Gawronska-Szklarz, Barbara ;
Wrzesniewska, Joanna ;
Siuda, Andrzej ;
Starzynska, Teresa ;
Drozdzik, Marek .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (10) :877-880
[44]   Pathogenesis of Helicobacter pylori infection [J].
Kusters, Johannes G. ;
van Vliet, Arnoud H. M. ;
Kuipers, Ernst J. .
CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (03) :449-+
[45]   Rabeprazole-based eradication therapy for Helicobacter pylori:: a large-scale study in Japan [J].
Kuwayama, H. ;
Asaka, K. ;
Sugiyama, T. ;
Fukuda, Y. ;
Aoyama, N. ;
Hirai, Y. ;
Fujioka, T. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) :1105-1113
[46]   Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study [J].
Kwon, Yong Hwan ;
Jeon, Seong Woo ;
Nam, Su Youn ;
Lee, Hyun Suk ;
Park, Ji Hey .
HELICOBACTER, 2019, 24 (04)
[47]   The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole [J].
Lee, Jeong Hoon ;
Jung, Hwoon-Yong ;
Choi, Kee Don ;
Song, Ho June ;
Lee, Gin Hyug ;
Kim, Jin-Ho .
GUT AND LIVER, 2010, 4 (02) :201-206
[48]   Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance [J].
Lee, Ju Yup ;
Kim, Nayoung ;
Kim, Min Soo ;
Choi, Yoon Jin ;
Lee, Jung Won ;
Yoon, Hyuk ;
Shin, Cheol Min ;
Park, Young Soo ;
Lee, Dong Ho ;
Jung, Hyun Chae .
DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (06) :1235-1243
[49]  
Lee Sang Bae, 2003, Korean J Gastroenterol, V42, P468
[50]   The prolongation effect of ilaprazole-based standard triple therapy forHelicobacter pylori [J].
Lee, Seung Woo ;
Moon, Sung Jin ;
Kim, Sae Hee ;
Jung, Sung Hee ;
Song, Kyung Ho ;
Kim, Sun Moon ;
Sung, Jae Kyu ;
Lee, Dong Soo .
MEDICINE, 2020, 99 (38) :E22137